Rationalizing the chemical space of protein-protein interaction inhibitors.

Protein-protein interactions (PPIs) are one of the next major classes of therapeutic targets, although they are too intricate to tackle with standard approaches. This is due, in part, to the inadequacy of today's chemical libraries. However, the emergence of a growing number of experimentally validated inhibitors of PPIs (i-PPIs) allows drug designers to use chemoinformatics and machine learning technologies to unravel the nature of the chemical space covered by the reported compounds. Key characteristics of i-PPIs can then be revealed and highlight the importance of specific shapes and/or aromatic bonds, enabling the design of i-PPI-enriched focused libraries and, therefore, of cost-effective screening strategies.

[1]  C. Chothia,et al.  The atomic structure of protein-protein recognition sites. , 1999, Journal of molecular biology.

[2]  Maykel Pérez González,et al.  Quantitative structure-activity relationship to predict differential inhibition of aldose reductase by flavonoid compounds. , 2005, Bioorganic & medicinal chemistry.

[3]  David C Fry,et al.  Protein-protein interactions as targets for small molecule drug discovery. , 2006, Biopolymers.

[4]  R. Hartmann,et al.  Prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods. , 2007, Journal of medicinal chemistry.

[5]  Milan Randic,et al.  Molecular Shape Profiles , 1995, J. Chem. Inf. Comput. Sci..

[6]  Alexander Dömling,et al.  Small molecular weight protein-protein interaction antagonists: an insurmountable challenge? , 2008, Current opinion in chemical biology.

[7]  Johann Gasteiger,et al.  Deriving the 3D structure of organic molecules from their infrared spectra , 1999 .

[8]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[9]  Michelle R Arkin,et al.  The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions. , 2009, Current opinion in chemical biology.

[10]  M. Randic,et al.  MOLECULAR PROFILES NOVEL GEOMETRY-DEPENDENT MOLECULAR DESCRIPTORS , 1995 .

[11]  Meir Glick,et al.  Streamlining lead discovery by aligning in silico and high-throughput screening. , 2006, Current opinion in chemical biology.

[12]  T. Berg Small-molecule inhibitors of protein-protein interactions. , 2008, Current opinion in drug discovery & development.

[13]  Claudio N. Cavasotto,et al.  Structure-based development of target-specific compound libraries. , 2006, Drug discovery today.

[14]  Jonathan C. Fuller,et al.  Predicting druggable binding sites at the protein-protein interface. , 2009, Drug discovery today.

[15]  Ozlem Keskin,et al.  Characterization and prediction of protein interfaces to infer protein-protein interaction networks. , 2008, Current pharmaceutical biotechnology.

[16]  T. Clackson,et al.  A hot spot of binding energy in a hormone-receptor interface , 1995, Science.

[17]  Christopher D. Thanos,et al.  Hot-spot mimicry of a cytokine receptor by a small molecule , 2006, Proceedings of the National Academy of Sciences.

[18]  Maykel Pérez González,et al.  In silico studies using Radial Distribution Function approach for predicting affinity of 1α,25-dihydroxyvitamin D3 analogues for Vitamin D receptor , 2006, Steroids.

[19]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[20]  K. Audouze,et al.  Emerging classes of protein-protein interaction inhibitors and new tools for their development. , 2004, Current opinion in chemical biology.

[21]  R. Nolen 'Between a rock and a hard place'. , 2002, Journal of the American Veterinary Medical Association.

[22]  Christian Cole,et al.  Side‐chain conformational entropy at protein–protein interfaces , 2002, Protein science : a publication of the Protein Society.

[23]  P. Chène Drugs Targeting Protein–Protein Interactions , 2006, ChemMedChem.

[24]  Hyeong Jun An,et al.  Estimating the size of the human interactome , 2008, Proceedings of the National Academy of Sciences.

[25]  Saul H Rosenberg,et al.  Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. , 2008, Journal of medicinal chemistry.

[26]  R. Nussinov,et al.  Principles of protein-protein interactions: what are the preferred ways for proteins to interact? , 2008, Chemical reviews.

[27]  B. Stockwell Exploring biology with small organic molecules , 2004, Nature.

[28]  Brian K. Shoichet,et al.  Virtual screening of chemical libraries , 2004, Nature.

[29]  R. Fåhraeus,et al.  In silico-in vitro screening of protein-protein interactions: towards the next generation of therapeutics. , 2008, Current pharmaceutical biotechnology.

[30]  D. E. Clark What has virtual screening ever done for drug discovery? , 2008, Expert opinion on drug discovery.

[31]  Gideon Schreiber,et al.  The molecular architecture of protein-protein binding sites. , 2005, Current opinion in structural biology.

[32]  J. Bajorath,et al.  Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.

[33]  Johann Gasteiger,et al.  Prediction of three-dimensional molecular structures using information from infrared spectra , 2000 .

[34]  Carl Kingsford,et al.  What are decision trees? , 2008, Nature Biotechnology.

[35]  R. Nussinov,et al.  Trp/Met/Phe hot spots in protein-protein interactions: potential targets in drug design. , 2007, Current topics in medicinal chemistry.

[36]  Michelle Arkin,et al.  Protein-protein interactions and cancer: small molecules going in for the kill. , 2005, Current opinion in chemical biology.

[37]  V. Helms,et al.  Transient pockets on protein surfaces involved in protein-protein interaction. , 2007, Journal of medicinal chemistry.

[38]  Jean-Christophe Rochet,et al.  Novel therapeutic strategies for the treatment of protein-misfolding diseases , 2007, Expert Reviews in Molecular Medicine.

[39]  David C. Fry Drug‐Like Inhibitors of Protein—Protein Interactions: A Structural Examination of Effective Protein Mimicry , 2009 .

[40]  A. Hamilton,et al.  Strategies for targeting protein-protein interactions with synthetic agents. , 2005, Angewandte Chemie.